ALGOTX
14.3.2023 08:02:19 CET | Business Wire | Press release
European biotech AlgoTx, the developer of first-in-class treatment ATX01 for chemotherapy-induced peripheral neuropathy (CIPN), announced today the success of a €20M Series B fundraising led by Relyens Innovation Santé / Turenne Capital , followed by UI Investissement, and historical investors Bpifrance through its Innobio 2 fund and Omnes Capital. Early and new business angel investors also significantly participated in this financing round, and AlgoTx secured an additional 1M€ in non-dilutive financing. The proceeds will be used to demonstrate the clinical efficacy of ATX01 in neuropathic pain.
Bervin Bouani, Investment Director at Turenne Capital, commented: “We are very proud to lead this strategic financing round to support AlgoTx to continue the clinical development of ATX01 lead candidate that has the potential to significantly improve the lives of patients with neuropathic pain. We look forward to working with Stéphane and his outstanding team to transform AlgoTx into a global pain player.”
Following the demonstration of ATX01’s early clinical safety and low systemic passage in Phase 1, the Phase 2 “ACT” study will now assess ATX01’s ability to reduce pain in adult CIPN patients – a program granted “fast-track” designation by FDA. In parallel, the Phase 2 “EASE” study will explore ATX01’s efficacy in the debilitating pain of erythromelalgia, a program for which ATX01 was granted “Orphan Disease Designation” in the US and Europe.
Stéphane Thiroloix, Founder & CEO of AlgoTx, says: “It is incredibly exciting to start the efficacy trials of ATX01, supported by such a high-profile syndicate of investors. We look forward to enrolling patients in our studies any day now.”
Over half of cancer patients treated with chemotherapy develop CIPN and experience sensory symptoms and pain in the hands and feet: loss of sensitivity, tingling, burning, cold and intense pain can persist for months to years after treatment. It affects over two million patients in the US and Europe and represents a leading cause for modification or interruption of chemotherapy. To this date, no therapeutic approach has offered a satisfactory response for patients and their caregivers, oncologists, neurologists and pain specialists.
« We are very pleased to support the AlgoTx team in the development of ATX01, driven by our belief in its significant impact in the treatment of CIPN and other neuropathic pain. AlgoTx can truly transform the lives of patients suffering from these conditions », says Pauline de Breteuil Senior Partner UI Investissement / FCPI Majycc Innovation Santé.
About AlgoTx
AlgoTx develops novel treatments for complex pain, with lead program ATX01 in Phase 2 in chemotherapy-induced peripheral neuropathy (NCT05593614) and erythromelalgia. More information at www.algotx.com
ACT study : ATX01 for the pain of ChemoTherapy, (NCT05593614). EASE study : Efficacy of ATX01 / Study in Erythromelalgia.
ABOUT TURENNE GROUP/RELYENS INNOVATION SANTÉ
Launched in 2014, Relyens Innovation Santé is is an evergreen venture capital vehicle specializing in health innovation controlled and owned by Relyens, a mutual insurance company specializing in the risk management of health, social and medical players. Relyens is the leading French player in medical civil liability. Advised by Turenne Santé (Health Division of Turenne Group), Relyens Innovation Santé's mission is to support the growth and development phases of innovative companies in the health sector.
Turenne Group, one of the leading private equity companies in France, has been supporting entrepreneurs for 23 years in their company’s innovation, development and transfer projects. As an independent player, the Group has assets of €1.4 billion under management. Its teams, made up of 68 professionals, including 52 investors, based in Paris, Lille (Nord Capital Partenaires), Lyon, Bordeaux, Marseille, Nice and Metz, support 290 business leaders, particularly in the healthcare, hospitality, innovation, BtoB services, and in the digital and impact sectors. With more than €300m, our healthcare team (Turenne Santé) invests across the entire value creation chain for healthcare companies through various investment approaches.
For more information: www.relyens.eu/fr / www.turennecapital.com
About Bpifrance and InnoBio 2
Bpifrance is the French national investment bank: it finances businesses – at every stage of their development – through loans, guarantees, equity investments and export insurances. Bpifrance also provides extra financial services (training, consultancy) to help entrepreneurs meet their challenges (innovation, export).
InnoBio 2 is an investment fund dedicated to life sciences, managed by Bpifrance, which is also one of the LPs alongside Sanofi, Boehringer Ingelheim, Takeda, Ipsen, Servier, BMS, European Investment Fund and Pasteur Mutualité. InnoBio 2, with €203 million, aims to invest in companies developing innovative products and services, close to or in early clinical development, with the objective of bringing them until the clinical proof of concept. InnoBio 2 takes minority equity stake in companies and can lead or co-lead the investment rounds.
For more information, please visit: www.bpifrance.com – Follow us on Twitter : @bpifrance - @BpifrancePresse
About Omnes
Omnes is a leading Paris-based European investor in private equity and infrastructure. With more than €5 billion in assets under management, Omnes provides companies with the equity capital they need to grow through its four core businesses: Venture Capital, Buyout & Growth Capital, Infrastructure and Co-Investment. With more than 30 trade sales and nearly 15 IPOs in 20 years (including Themis Bioscience, Biovex, arGEN-X, Novaled and Direct Energie), Omnes Venture Capital team is a leading French player in financing innovative SMEs with dual expertise in the deep-tech and healthcare sectors. Omnes is committed to ESG issues and has set up the Omnes Foundation in aid of children’s charities. The company is also a signatory to the United Nations Principles for Responsible Investment (PRI). www.omnescapital.com
About UI Investissement
UI Investissement is an independent, specialized company in the development of unlisted French companies with €1.5 billion under management. For over 50 years, UI Investissement has been committed to work alongside the managers of growing SMEs and STIs to help them emerge as economically and sustainably successful businesses through its focus on three areas: health, agro-business, and business services.
With its expertise, UI Investissement provides support to companies in the health sector at all stages of their development and plays a central role in the ecosystem. It is through the Majycc Innovation Santé fund that UI Investissement supports entrepreneurs who aim to be the architects of tomorrow's health. The roots of Majycc Innovation Santé are deeply connected to the DNA of several private clinic groups, nursing home groups, and mutual health insurance companies, representing entrepreneurship, health and human values, respect for corporate culture, and the projects of the individuals who build them.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005169/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Introduces BlueVerse™ OneToken with Harnessing Capabilities to Optimize Token Spend24.9.2026 10:30:00 CEST | Press release
Helps organizations run and scale AI with greater control, transparency and accountability LTM, the Business Creativity partner to the world’s largest enterprises, today announced BlueVerse™ OneToken, a workload routing and governance layer with Harnessing Capabilities that automatically channels enterprise AI requests to the right model at the right cost. As enterprises scale agentic workflows, requests are often routed to expensive frontier models even when lower-cost options can deliver the required outcome. BlueVerse OneToken manages model selection across workloads including code, voice, service, research and agents, matching each task with the most appropriate model, based on the client’s quality, security and performance requirements. Clients can deploy BlueVerse OneToken over their existing AI environment, giving them a single subscription for AI consumption enabling them to consume AI through their existing cloud providers using OneToken plug-ins, available across AWS, Google
MVC Group Acquires Tailfin, Entering the Premium Bikepacking Sector24.9.2026 10:30:00 CEST | Press release
The acquisition expands MVC's portfolio with best-in-class solutions in a category highly complementary to Castelli and Sportful's technical cycling apparelTailfin will accelerate its international expansion through synergies with MVC Group's global platform MVC Group, a group specialising in technical apparel for cycling and outdoor sports, announces the acquisition of Tailfin, the global leader in the premium technical bikepacking segment. Founded in Bristol in 2017 by Nick Broadbent – CEO, mechanical engineer and product designer – Tailfin has rapidly established itself as a leading international name in premium bikepacking bags, racks and accessories, combining design and performance with a strong focus on innovation. The company has developed proprietarytechnologies protected by more than 20 granted and pending patents, building a leading position based on engineering excellence, materials research and rigorous product development and validation processes. Over the past five years
CAIRDAC Announces the Appointment of Raymond W. Cohen as Chairman of its Board of Directors24.9.2026 09:49:00 CEST | Press release
CAIRDAC, SA, a pre-revenue stage medtech company developing a leadless, self-powered cardiac pacemaker (Autonomous Leadless Pacing System), today announced the appointment of Raymond W. Cohen as chairman of its board of directors. “We are thrilled to welcome Mr. Cohen to the CAIRDAC board of directors,” said Edouard Fonck, Chief Executive Officer of CAIRDAC, “Ray’s extensive track record in leading, scaling and exiting medical technology companies will, no doubt, be invaluable as we advance this exciting project.” Mr. Cohen, an accredited public company director and accomplished medical technology executive, has over four decades of medtech industry experience. He was the co-founder and CEO of Axonics, Inc. (Nasdaq: AXNX) a global leader in implantable neuromodulation devices that completed its initial public offering in 2018. Under his leadership, Axonics was recognized as the fastest-growing technology company in North America generating over $1.2 billion in revenue in the four years
Glass Lewis and Clarity AI Join Forces to Integrate Sustainability, Governance and Stewardship24.9.2026 09:30:00 CEST | Press release
Integrated platform will connect investment and stewardship decisions through trusted data, AI analytics, and technology Glass Lewis and Clarity AI today announced their combination, merging Clarity AI’s advanced technology, deep sustainability data, AI analytics, and strong European market presence with Glass Lewis’ global expertise across corporate governance, proxy voting and investment stewardship. The strategic combination significantly expands the firms’ ability to serve European institutional investors and companies through enhanced local market expertise, broader sustainability capabilities and faster product development that addresses Europe’s evolving regulatory and stewardship requirements. The integrated platform fills a solutions gap as institutional investors increasingly seek to bring together investment analysis, sustainability, governance, engagement and voting rather than manage them through separate systems, datasets and workflows. At the same time, companies are con
Wolters Kluwer integrates Libra AI workflows into monKEY for Belgian tax professionals24.9.2026 09:00:00 CEST | Press release
The add-in of Libra by Wolters Kluwer brings AI capabilities directly into monKEY’s trusted tax research environment and marks an important milestone in further expanding Libra’s presence across different customer segments Wolters Kluwer Legal & Regulatory today announced the integration of Libra AI workflows in monKEY, its research platform for tax professionals in Belgium. The add-in of Libra by Wolters Kluwer enables customers to directly access Libra’s AI capabilities from the trusted research environment in monKEY, combining generative AI with tax research based on long-trusted expert content. “By integrating Libra into monKEY, we are taking another important step towards connected, AI-powered workflows for our customers,” said Rimco Spanjer, Vice President & Managing Director, Wolters Kluwer Legal & Regulatory Benelux. “We are bringing together the power of AI and the trusted, up-to-date tax content professionals rely on every day. This helps them reach relevant insights faster w
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom